InsidersTradesSigma
Total declarations
Company
▲ Purchases (18 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
18
Disclosed sells
0
T+90 hit rate
18%
T+90 mean return
-12.7%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by FREEMAN KEVIN D, Director. Officer active across 1 company, notably Galectin Therapeutics INC. Aggregated, 19 filings have been published. Breakdown: 18 buys · 0 sell. Total volume traded: €154k. Activity tracked since 23 September 2021. The latest transaction was filed on 17 July 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations19 total
5,000 shares@ US$2.899Common StockSEC:0001133416-25-000033:0
Ideal exit: 13 Apr 2026 (T+270)
10,000 shares@ US$0.81343.6% of flowCommon StockSEC:0001133416-24-000062:0
Ideal exit: 20 Sept 2025 (T+270)
1,300 shares@ US$2.641.4% of flowCommon StockSEC:0001133416-24-000058:0
Ideal exit: 14 Jul 2025 (T+270)
5,000 shares@ US$2.705.7% of flowCommon StockSEC:0001133416-24-000056:0
Ideal exit: 13 Jul 2025 (T+270)
2,500 shares@ US$2.37992.5% of flowCommon StockSEC:0001133416-24-000044:0
Ideal exit: 17 Mar 2025 (T+270)
2,500 shares@ US$2.983.2% of flowCommon StockSEC:0001133416-24-000038:0
Ideal exit: 17 Jan 2025 (T+270)
2,063 shares0Common StockSEC:0001133416-24-000036:0
10,000 shares@ US$1.416.5% of flowCommon StockSEC:0001133416-22-000093:0
Ideal exit: 25 Jul 2023 (T+270)
5,000 shares@ US$1.32990.0044% mcap3.7% of flowCommon StockSEC:0001133416-22-000063:0
Ideal exit: 13 Feb 2023 (T+270)
5,000 shares@ US$1.710.0056% mcap4.7% of flowCommon StockSEC:0001133416-22-000057:0
Ideal exit: 13 Jan 2023 (T+270)
5,000 shares@ US$1.96120.0061% mcap5.1% of flowCommon StockSEC:0001133416-22-000008:0
Ideal exit: 16 Oct 2022 (T+270)
5,000 shares@ US$1.96120.0061% mcap5.1% of flowCommon StockSEC:0001133416-22-000010:0
Ideal exit: 16 Oct 2022 (T+270)
5,000 shares@ US$2.280.0071% mcap6.0% of flowCommon StockSEC:0001133416-21-000025:0
Ideal exit: 2 Sept 2022 (T+270)
5,000 shares@ US$2.280.0071% mcap6.0% of flowCommon StockSEC:0001133416-21-000027:0
Ideal exit: 11 Sept 2022 (T+270)
5,000 shares@ US$2.340.0072% mcap6.1% of flowCommon StockSEC:0001133416-21-000023:0
Ideal exit: 2 Sept 2022 (T+270)
2,000 shares@ US$3.170.0038% mcap3.2% of flowCommon StockSEC:0001133416-21-000017:0
Ideal exit: 26 Jul 2022 (T+270)
2,000 shares@ US$3.190.0038% mcap3.2% of flowCommon StockSEC:0001133416-21-000013:0
Ideal exit: 18 Jul 2022 (T+270)
3,000 shares@ US$3.36890.0061% mcap5.1% of flowCommon StockSEC:0001133416-21-000011:0
Ideal exit: 16 Jul 2022 (T+270)
3,000 shares@ US$3.8770.0069% mcap5.9% of flowCommon StockSEC:0001140361-21-032248:0
Ideal exit: 20 Jun 2022 (T+270)
19 of 19 declarations
About FREEMAN KEVIN D
Kevin D. Freeman is an executive at Galectin Therapeutics Inc.
